United Therapeutics Telemedicine To Support Pulmonary Hypertension Drugs
Executive Summary
United Therapeutics will provide telemedicine services for a fee to patients and physicians using its pulmonary hypertension therapies when they are approved, according to the company's prospectus for an initial public offering of stock valued at $86.3 mil.